Trial Profile
A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Doctaxel and Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) in Men With Hormone Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ALLIANCE
- 04 Mar 2024 Results discovering clinical and pharmacogenetic factors associated with bevacizumab-related gastrointestinal hemorrhage, published in the Pharmacogenomics Journal
- 01 Feb 2022 Results from TARGET study and four (CALGB/Alliance) clinical trials identifying predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach published in the Pharmacogenomics Journal
- 06 Oct 2021 Results of a meta-analysis of a for clinical studies assessing genome-wide association with either hypertension or proteinuria across the different studies (NCT00785291, NCT00601900, NCT00088894 and NCT00110214) published in the British Journal of Cancer